ModifiedCignaPolicy 0019

Minimally Invasive Anti-Reflux Procedures and Peroral Endoscopic Myotomy (POEM) Procedures

Defines Cigna's coverage stance for esophageal POEM, gastric POEM (G-POEM), diverticular POEM (D-POEM), and selected endoscopic/laparoscopic anti-reflux procedures for achalasia, gastroparesis, and GERD under Cigna-administered plans.

Policy Summary

PayerCigna

PolicyMinimally Invasive Anti-Reflux Procedures and Peroral Endoscopic Myotomy (POEM) Procedures

Policy CodePolicy 0019

Change TypeCoverage revisiontemplate update

Effective DateSep 15, 2025

Next Review DateAug 15, 2026

Key ActionFor G-POEM prior authorization, document prior conservative therapy and objective testing including gastric emptying study and GCSI scores.

SourceLink

POLICY UPDATE CHANGES

Removed non-coverage statement for Zenker peroral endoscopic myotomy (Z-POEM).

No changes to coverage (annual review statement).

Changed from not covered to covered for gastric peroral endoscopic myotomy (G-POEM) for a small subset of patients.

Updated to new template and formatting standards.

≥18Min age for POEM

Eckardt >3Eckardt threshold

>20% @4hG-POEM GES threshold

65.2%G-POEM 36‑mo success

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

MultipleProcedures experimental

Coverage Criteria and Policy Statements

inv-01: Esophageal POEM (Achalasia) — medically necessary when ALL criteria are met

Esophageal peroral endoscopic myotomy (POEM) is considered medically necessary when ALL of the following criteria are met:

Esophageal POEM coverage criteria: The individual is age 18 years or older.

From policy: chunk 5

Esophageal POEM coverage criteria: Achalasia type I, II, or III is diagnosed using esophageal manometry (Chicago Classification).

From policy: chunk 5

Esophageal POEM coverage criteria: Eckardt symptom score is greater than 3.Eckardt > 3

From policy: chunk 5

inv-02: Gastric POEM (G-POEM) for Refractory Gastroparesis — medically necessary when ALL criteria are met

Gastric peroral endoscopic myotomy (G-POEM) is considered medically necessary for treatment of refractory gastroparesis when ALL of the following criteria are met:

G-POEM coverage criteria: Absence of mechanical obstruction confirmed by esophagogastroduodenoscopy (EGD).

From policy: chunks 5 and 12

G-POEM coverage criteria: Gastric emptying scintigraphy (GES) confirming delayed gastric emptying with gastric retention > 20% at four hours.Retention > 20% at 4 hours

From policy: chunks 5 and 12

G-POEM coverage criteria: Chronic, intractable nausea and vomiting secondary to gastroparesis (symptom burden consistent with refractory disease).

From policy: chunks 5 and 12

inv-03: G-POEM — candidate selection (evidence summary & selection considerations)

Evidence indicates G-POEM may provide symptomatic improvement in selected patients with refractory gastroparesis; candidate selection considerations observed in studies include:

G-POEM candidate selection: Age ≥ 18 years AND confirmed diagnosis of gastroparesis with persistent symptoms despite dietary control and prokinetic treatment for ≥ 6 months.

Derived from inclusion criteria in cohort and prospective studies (Labonde, Vosoughi; chunks 18,20)

G-POEM candidate selection: Documented baseline and follow-up symptom assessment (e.g., GCSI) and objective gastric emptying testing (GES) to document delayed gastric emptying and assess response.GES retention documented (see coverage criteria)

Studies report use of GCSI and GES for outcomes (chunks 18,20,24,25)

Etiology and predictors: Consideration of gastroparesis etiology (diabetic, idiopathic, postsurgical) and predictors of response; some series report higher long-term success in certain etiologies and with specific preprocedure characteristics.

inv-04: D-POEM — evidence insufficiency; not established efficacy/safety

Diverticular peroral endoscopic myotomy (D-POEM) has only limited case series and small prospective studies; the evidence is insufficient to establish efficacy and safety.

D-POEM evidence stance: Available literature consists primarily of small prospective studies and case series (patient populations typically 11–25) with limited follow-up; insufficient evidence to support routine coverage for esophageal diverticula or other indications.

From literature review: chunk 28

inv-05: Radiofrequency (Stretta) — mixed evidence summary and implications

Endoscopic radiofrequency therapy (Stretta) shows mixed evidence; randomized trials and meta-analyses report inconsistent results that affect coverage implications.

Stretta evidence summary: Some cohort and uncontrolled studies report symptomatic improvement, PPI reduction, and improved quality-of-life; however, randomized sham-controlled trials (e.g., Zerbib et al.) and systematic reviews/meta-analyses found no consistent physiologic or clinical benefit over sham or medical therapy and rated evidence quality as low to very low.

RCTs and meta-analyses summarized in chunks 32,34,35

Coverage implications: Given conflicting RCT evidence and heterogeneity of observational data, Stretta should be considered cautiously and may be denied or considered not medically necessary when offered for indications lacking supportive evidence or objective testing.

Policy notes mixed evidence and potential noncoverage implications (chunks 31-35)

inv-06: Study-derived patient selection considerations — common enrollment characteristics

Typical enrollment characteristics observed across endoscopic anti-reflux and related device studies included:

Typical study inclusion: Persistent or daily GERD symptoms despite PPI therapy; age ≥ 18 years; small or no hiatal hernia (commonly ≤ 2–3 cm); pathologic esophageal acid exposure or erosive esophagitis within trial-specific limits.

Derived from multiple study inclusion descriptions (chunks 36,37,53,65)

Device/regulatory considerations: Device FDA clearance/approval status and specific device instructions influenced trial eligibility; some devices (e.g., EsophyX, MUSE) have regulatory summaries while others (e.g., GERDx) lacked FDA approval in reports.

Device regulatory status discussed in chunks 45,53

inv-07: Study-derived candidate eligibility for TIF — trial inclusion criteria

Studies generally treated transoral incisionless fundoplication (TIF) as appropriate when ALL of the following were met:

TIF trial eligibility: Age ≥ 18 years; chronic troublesome GERD despite optimized PPI therapy; objective evidence of pathologic reflux (abnormal pH monitoring or erosive esophagitis) when required by protocol; hiatal hernia ≤ 2–3 cm and BMI below study-specific thresholds (commonly <30–35 kg/m2); exclusion of advanced esophagitis (LA grade C/D), long-segment Barrett's esophagus, major motility disorders, and prior esophageal or gastric surgery.

Derived from multiple RCTs and systematic reviews (chunks 69,72,65,70)

inv-08: Candidate selection criteria for TIF or LINX derived from clinical studies

Patient selection criteria for TIF or LINX derived from clinical studies commonly included ALL of the following:

Core inclusion criteria: Age 18–80 years (varied by study); chronic GERD symptoms for ≥ 6 months to >1 year; PPI-dependence or persistent symptoms despite daily PPI therapy; objective evidence of reflux (abnormal pH or erosive esophagitis) or troublesome regurgitation/extraesophageal symptoms per Montreal criteria.

Derived from multiple randomized trials (chunks 72,74,75)

Anatomic and physiologic constraints: Hiatal hernia ≤ 2–3 cm (study-specific), Hill grade ≤ II, esophagitis less than grade C/D, absence of Barrett's esophagus >2–3 cm, and normal or near-normal esophageal motility on manometry.

Exclusions and constraints summarized across trials (chunks 72,75,77)

Functional testing requirements: Objective testing such as 24–48 hour pH or pH-impedance demonstrating abnormal acid exposure, and esophageal manometry to exclude major motility disorders were commonly required.Examples: percent time pH<4 >5.3% (48-h Bravo) or Demeester >14.7 in some trials

inv-09: Expected clinical outcomes reported in studies

Expected clinical outcomes reported in trials and observational studies included:

Symptom and medication outcomes: Improvements in validated symptom scores (GERD-HRQL, RDQ, RSI) and substantial rates of PPI cessation or dose reduction in selected cohorts (reported ranges vary by device and study, e.g., PPI cessation ~64–90% in some series).

Reported across TIF, MUSE, and MSA studies (chunks 65,70,82,84)

Objective physiologic outcomes: Improvement in esophageal acid exposure (DeMeester and percent time pH<4) reported inconsistently; normalization rates varied and sometimes declined over time despite symptom improvements.

Objective metrics variably normalized in trials (chunks 65,72,77)

Adverse events and device issues: Reported complications include dysphagia, gas/bloating, rare serious events (perforation, pneumonia); device explant/removal rates and reoperation vary (e.g., LINX explant rates and MSA device removals reported), and pooled major complication rates for some endoscopic approaches ~3.2% in observational reviews.

Device safety signals and complication rates summarized in chunks 82,84,87

inv-10: Coverage-related clinical criteria — proxies for medical necessity

Clinical coverage considerations reflected in the literature (used as proxies for medical necessity criteria) include:

MSA/LINX typical inclusion: Age 18–75 years; chronic GERD symptoms ≥ 6 months; objective pathologic esophageal acid exposure; persistent symptoms despite daily PPI therapy.

Pivotal and follow-up LINX studies used these criteria (chunks 102,104)

Common exclusion criteria: Hiatal hernia > 3 cm; esophagitis Los Angeles grade C/D; BMI >35 kg/m2; Barrett's esophagus; major esophageal motility disorders; allergy to device materials.

Exclusions reported across LINX/MSA studies (chunk 102)

Prior therapy requirement: Failure to achieve adequate reflux control on daily PPI therapy; many trials required documented PPI trial prior to device therapy.

Randomized designs and crossover cohorts required PPI optimization (chunks 93,95)

inv-11: POEM – Achalasia — policy coverage headline

Considered medically necessary when criteria in the applicable policy statements are met:

POEM coverage headline: POEM (CPT 43497) is considered medically necessary for the treatment of achalasia when the coverage criteria (age ≥ 18, manometric diagnosis of achalasia type I–III, Eckardt score > 3) are satisfied.

Procedure code and coverage statement: chunk 119

inv-12: G-POEM – Refractory Gastroparesis — policy coverage headline

Considered medically necessary when criteria in the applicable policy statements are met:

G-POEM coverage headline: G-POEM is considered medically necessary for treatment of refractory gastroparesis when the clinical criteria are met and the procedure is reported with appropriate unlisted CPT codes (e.g., 43999, 43499).

Procedure codes and policy stance: chunks 120 and 112; clinical context: chunk 12

G-POEM procedural context: G-POEM should be considered for selected refractory patients after failure of conservative therapy and performed in tertiary centers with expertise, with documented GCSI and GES pre- and post-procedure as reported in society guidance.

AGA guidance and study recommendations cited (chunk 112; chunks 18-25 for supporting studies)

inv-13: Endoscopic and Laparoscopic Anti-reflux Procedures (GERD) — policy stance summary

Stance on endoscopic and laparoscopic anti-reflux procedures for GERD reflected in the policy:

Anti-reflux procedures experimental stance: Endoscopic or laparoscopic anti-reflux procedures performed for the treatment or management of GERD (including radiofrequency energy [Stretta], endoluminal gastroplasty/gastroplications [EsophyX, MUSE, GERDx], injection/implantation techniques, magnetic sphincter augmentation [LINX], and RAP/OverStitch) are designated Experimental/Investigational/Unproven when reported with the listed CPT codes.

Policy lists procedures and associated codes as experimental/investigational (chunk 120) and summarizes mixed evidence for Stretta (chunks 31-35)

Esophageal POEM is covered only for achalasia meeting the policy criteria. Specifically, POEM is considered medically necessary when the patient is ≥ 18 years old, has achalasia type I, II, or III confirmed by esophageal manometry, and an Eckardt score > 3. The policy explicitly states that Esophageal POEM for any other indication is not medically necessary and should not be billed or authorized for non‑achalasia uses.

Diverticular POEM (D‑POEM) has been described in small case series and limited prospective studies (typical cohorts n=11–25) with short follow‑up. Published reports are insufficient to establish safety and efficacy for treatment of esophageal diverticula or other indications; therefore, D‑POEM is considered experimental, investigational, or unproven and is not supported for routine coverage pending larger, well‑designed studies.

Trials of endoscopic anti‑reflux or related minimally invasive procedures commonly excluded patients with specific anatomic, physiologic, or medical conditions. Examples of trial‑based exclusion conditions that may render a patient ineligible include uncontrolled severe medical illness, prior esophageal or gastric surgery, pregnancy, and other protocol‑specified contraindications. These study exclusions are referenced to reflect populations in which procedural efficacy and safety were evaluated and should inform candidate selection for coverage review.

Common exclusion criteria observed across TIF, LINX, and other endoscopic GERD trials include: hiatal hernia greater than study limits (commonly >2 cm), Los Angeles grade C or D esophagitis, Barrett’s esophagus >2 cm in length, prior esophageal or gastric surgery, body mass index thresholds used in trials (often BMI >30–35), and major esophageal motility disorders. Patients with these findings were typically excluded from the trials and therefore are often considered poor candidates for these endoscopic procedures in routine practice.

Several injection/implantation products and bulking agents (for example, Gatekeeper, Enteryx, PMMA, and Durasphere) are not indicated or were withdrawn for GERD indications. When devices are not FDA‑approved for GERD or have been removed from the market, their use may trigger coverage denial or require special review; lack of regulatory approval and limited evidence affect the policy’s noncoverage stance for such devices.

Examples of exclusions cited in the policy and literature include large hiatal hernia (>3 cm), advanced esophagitis (Los Angeles grade C or D), Barrett’s esophagus exceeding trial length limits, elevated BMI thresholds used by investigators (commonly >30–35 kg/m2), and major esophageal motility disorders. These conditions were associated with study exclusion criteria or device labeling and represent scenarios with limited supporting evidence for the procedures.

Endoscopic or laparoscopic anti‑reflux procedures (including listed CPT codes such as 43210, 43236, 43257, 43284, 43289, 43499, 43659) are designated in this policy as Experimental/Investigational/Unproven for treatment of GERD or other indications. This designation reflects inconsistent randomized trial results (for example, radiofrequency/Stretta randomized sham trial) and heterogeneous evidence across endoscopic therapies, and it means these procedures are not supported for routine coverage under the listed codes.

The references section in the document lists bibliographic citations supporting the literature review but does not itself state explicit coverage exclusions. The bibliography should be used as supporting evidence when reviewing cases, while coverage determinations rely on the policy’s explicit coverage and exclusion statements.

Revision history documents that a prior non‑coverage statement for Zenker peroral endoscopic myotomy (Z‑POEM) was removed during the annual review. This edit is recorded in the revision notes and may affect prior determinations; providers should reference the current policy version when submitting claims.

The policy reiterates that Esophageal POEM is not medically necessary for any indication other than achalasia (types I–III) meeting the stated criteria (age ≥ 18 years, manometric diagnosis, and Eckardt score > 3). This restatement emphasizes that non‑achalasia uses are excluded from coverage.

A high‑quality randomized, double‑blind, sham‑controlled trial of esophageal radiofrequency energy (Stretta) did not demonstrate significant benefit versus sham for PPI‑refractory heartburn in the intention‑to‑treat analysis. Given these trial results and mixed findings in systematic reviews, Stretta’s efficacy remains unproven in randomized evidence, which supports the policy’s cautious stance on coverage for radiofrequency treatment when used for PPI‑refractory heartburn alone.

EndoCinch and other early suturing systems demonstrated frequent loss of intact sutures and failed to show durable improvement in objective acid exposure compared with sham. Long‑term and controlled data are lacking, and durability concerns remain a limitation for coverage of these suturing/plication approaches.

Systematic reviews and meta‑analyses of transoral incisionless fundoplication (TIF) and related plication techniques conclude that these endoscopic plication procedures cannot be routinely recommended as an alternative to optimized medical therapy or traditional surgical fundoplication. While selected trials reported symptom improvement and PPI cessation in some patients, objective physiologic normalization (pH) and long‑term durability were inconsistent, supporting the policy’s limited stance and need for further comparative evidence.

Evidence for the MUSE (Medigus Ultrasonic Surgical Endostapler) system is limited to small prospective series and case reports (typical cohorts n=14–66). Randomized controlled data with long‑term follow‑up are lacking, which constrains conclusions about comparative effectiveness and underlies the policy’s conservative coverage approach for MUSE.

Overall, the body of evidence for endoscopic therapies for GERD is heterogeneous, with many studies reporting short‑term follow‑up, variable objective outcomes, and inconsistent durability. The policy emphasizes the need for larger, longer‑term randomized and comparative studies to clarify effectiveness and long‑term safety before broader coverage can be supported for many of these endoscopic and laparoscopic anti‑reflux procedures.

The policy explicitly states that use of the listed endoscopic or laparoscopic procedure codes to report treatments for GERD is considered unproven and not supported by this policy segment. These codes include CPT codes such as 43210, 43236, 43257, 43284, 43289, 43499, and 43659, which are designated Experimental/Investigational/Unproven for GERD indications.

The references section contains bibliographic citations only and does not itself state any procedures as not medically necessary. These citations are provided to support the literature review and clinical rationale in the policy but do not replace the explicit coverage and exclusion statements in the policy text.

The referenced revision notes and surrounding chunks do not include additional specific 'not medically necessary' conditions beyond those explicitly stated elsewhere in the policy. Absence of explicit non‑coverage statements in those reference chunks does not change the policy’s stated coverage and exclusion positions.

Coding, CPT/Device Identifiers, and Key Clinical Thresholds

Codes referencedmixed

No codes listed

Covered CPT Codes (POEM)CPTCovered

43497

Lower esophageal myotomy, transoral (ie, peroral endoscopic myotomy [POEM])

Covered / Unlisted Codes (G-POEM and related)CPTCovered

43999	Unlisted procedure, stomach
43499	Unlisted procedure, esophagus

Experimental/Investigational / Not Covered Codes (endoscopic or laparoscopic anti-reflux procedures)CPTNot Covered

43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed.
43236	Esophagogastroduodenoscopy, flexible, transoral; with directed submucosal injection(s), any substance.
43257	Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease.
43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (ie, magnetic band), including cruroplasty when performed.
43289	Unlisted laparoscopy procedure, esophagus.
43659	Unlisted laparoscopy procedure, stomach

Referenced FDA device PMA/510(k) identifiersmixed

P100049	FDA PMA - LINX Reflux Management System
K000245	FDA 510(k) - CSM Stretta System
K071651	FDA 510(k) - EsophyX System
K142113	FDA 510(k) - EsophyX2 HD Device
K152317	FDA 510(k) - Mederi Therapeutics Stretta Catheter
K132151	FDA 510(k) - Medigus SRS Endoscopic Stapling System (MUSE)
K181141	FDA 510(k) - OverStitch Endoscopic Suturing System
K210266	FDA 510(k) - OverStitch Sx Endoscopic Suturing System

Eckardt score threshold used in criteria

Eckardt score thresholdEckardt symptom score > 3

Eckardt score rangeScale 0–12, points for weight loss, dysphagia, retrosternal pain, regurgitation

Clinical stage mapping0–1 = stage 0; 2–3 = stage I; 4–6 = stage II; >6 = stage III

Gastric retention on GES threshold for G-POEM

Gastric retention threshold (GES)> 20% gastric retention at 4 hours on gastric emptying scintigraphy (GES)

Requirement

Prior Authorization, Documentation, and Billing Guidance

Prior Authorization

Medical Necessity / Prior Authorization Overview

Medical necessity review required — requests are reviewed per the policy's medical necessity criteria. Prior authorization may be required per the member's plan and the main policy prior authorization code lists; consult the main policy for applicable prior auth codes and processes.

See main policy for specific prior authorization codes and lists.

Documentation Required

Prior Authorization: Required Objective and Pre-procedure Documentation

Prior authorization is recommended for anti-reflux procedures (LINX, TIF, Stretta) and for G-POEM. For GERD-specific procedures, provide objective documentation of pathologic reflux (eg, abnormal ambulatory pH monitoring or Bravo pH with % time pH<4 above accepted thresholds) and documentation of prior inadequate response to optimized medical therapy (PPI use/history). For G-POEM, include age, diagnosis, symptom indices (eg, GCSI), gastric emptying study results demonstrating delayed gastric emptying, and prior conservative therapies (dietary modifications, prokinetics).

Background and Evidence Summary

Background: Achalasia is a primary esophageal motility disorder characterized by absent or reduced peristalsis in the distal esophagus and impaired relaxation of the lower esophageal sphincter (LES). Peroral endoscopic myotomy (POEM) is an endoscopic technique that creates a myotomy of the LES and is an endoscopic alternative to surgical Heller myotomy; POEM provides the ability to perform a longer myotomy but does not include an anti‑reflux component. The policy’s coverage position for POEM is based on these clinical characteristics and the available comparative evidence.

Additional context: Evidence for endoscopic therapies for GERD is mixed and heterogeneous. Systematic reviews highlight short‑term physiologic and symptom improvements in some studies but note limited long‑term randomized data and variable durability. This heterogeneity supports the policy’s cautious approach and the need for further high‑quality, long‑term evidence before broader coverage of many endoscopic anti‑reflux procedures can be recommended.

Definitions and Key Terms

Achalasia definition and classification

DefinitionAchalasia: reduced/absent peristalsis in distal esophagus, incomplete LES relaxation, increased resting LES tone

Manometric classificationChicago Classification via HRM defines Types I, II, III based on pressurization and contractile patterns

Type descriptorsType I: aperistalsis, no pressurization; Type II: panesophageal pressurization ≥20% swallows; Type III: premature/spastic contractions

Gastroparesis definition

DefinitionGastroparesis: chronic motility disorder with objectively delayed gastric emptying without mechanical obstruction

SymptomsNausea, vomiting, early satiety, bloating, upper abdominal pain

Policy Revision History

2025-09-15annual_reviewLatest

Removed non-coverage statement for Zenker peroral endoscopic myotomy (Z-POEM).

2024-08-15annual_review

Annual review with no changes to coverage reported.

2023-10-15coverage_change

Changed coverage status for gastric peroral endoscopic myotomy (G-POEM) from not covered to covered for a small subset of patients and updated document to new template/formatting standards.

Policy Summary

PayerCigna

PolicyMinimally Invasive Anti-Reflux Procedures and Peroral Endoscopic Myotomy (POEM) Procedures

Policy CodePolicy 0019

Change TypeCoverage revisiontemplate update

Effective DateSep 15, 2025

Next Review DateAug 15, 2026

Key ActionFor G-POEM prior authorization, document prior conservative therapy and objective testing including gastric emptying study and GCSI scores.

SourceLink

On This Page

threshold":"","note":"From policy: chunks 5 and 12","children":[]}

Study predictors and scoring systems reported (Labonde et al.; chunk 18)

Safety and technical outcomes: High technical success rates reported (near 100%) with pooled adverse event rates in meta-analyses around 6.8%; follow-up durations and quality of evidence vary and long-term durability is incompletely defined.

Meta-analyses and systematic reviews report technical success and AE rates (chunks 24,25)

Testing thresholds used in trials (chunks 69,72)

RAP evidence quality: Resection and Plication (RAP/OverStitch) has limited evidence from small case series and short follow-up; further well-designed long-term studies are required before routine coverage.

Limited cohorts and preliminary reports cited (chunks 105,106)

Delayed gastric emptying must be confirmed by GES in absence of mechanical obstruction

Clinical documentationGES results used alongside GCSI and documented refractory symptoms

Integrated relaxation pressure (IRP) manometric threshold referenced

IRP manometric threshold> 15 mmHg integrated relaxation pressure (IRP) indicates abnormal LES relaxation

ContextIRP > 15 mmHg used to define abnormal LES relaxation in achalasia diagnosis

UseApplied with high-resolution manometry (HRM) and Chicago Classification

Abnormal esophageal acid exposure examples used in trials (pH thresholds/Demeester)

Trial example — Bravo pH thresholdPercent time pH < 4 > 5.3% on 48-hour Bravo testing (used in TEMPO trial)

Demeester score exampleDeMeester score thresholds cited (eg, >14.7 reported in some studies) as trial comparators

Alternate trial thresholdSome trials used percent time pH <4 ≥ 4.0% or similar pH-impedance cutoffs depending on protocol

Objective GERD documentation: abnormal pH monitoring, endoscopic findings, or documented PPI-refractory disease.
G-POEM required documentation: age, diagnosis, symptom scores (GCSI), gastric emptying study (delayed), prior dietary/prokinetic/antiemetic trials.

Prior Authorization

Confirm Indication and Device Regulatory Status

For device-based therapies, prior authorization should confirm the indication and device regulatory status. Provide FDA regulatory identifiers (PMA or 510(k) summaries) or device labeling when available to validate device indication (eg, LINX PMA P100049; EsophyX 510(k) summaries). If device is not FDA-approved or has been withdrawn, coverage may be impacted.

Include device model, implant/revision intent, and FDA PMA/510(k) summary reference when available.
LINX PMA (P100049) referenced in FDA documents.

Prior Authorization

Prior Authorization / Coverage Headline

Prior authorization / coverage headline: POEM (CPT 43497) and G-POEM (unlisted CPT codes 43999/43499 as applicable) are listed as covered when applicable criteria are met. Other endoscopic or laparoscopic anti-reflux procedures (specific CPTs listed in policy) are considered experimental/investigational and not covered.

Covered codes: POEM (43497); G-POEM reported with unlisted stomach/esophagus codes (43999, 43499) when criteria met.
Not covered/experimental codes listed in policy (eg, 43210, 43257, 43284, 43289, 43659).

Prior Authorization

Prior Authorization / Indication Considerations for LINX and TIF

Transoral incisionless fundoplication (TIF) and LINX have device-specific labeling and selection criteria (eg, small hiatal hernia, Hill grade I-II, no advanced esophagitis, BMI thresholds). Prior authorization should document that patients meet these indication-specific selection criteria.

TIF selection: chronic GERD ≥6 months, abnormal esophageal acid exposure, hiatal hernia ≤2 cm (or repaired to ≤2 cm), Hill grade I–II.
LINX selection: pathologic reflux confirmed, prior optimized medical therapy, exclusion for large hiatal hernia (>3 cm), BMI >35, or severe esophagitis/Barrett's per device labeling.

Note

Stretta — Evidence and Authorization Considerations

Stretta (radiofrequency) has mixed evidence. A high-quality sham-controlled RCT (Zerbib et al., 2020) found no significant difference vs sham; other uncontrolled or small studies report symptom improvements but overall evidence quality is low and outcomes are conflicting. The ACG does not recommend Stretta as an alternative to medical or surgical antireflux therapies.

Documented trial-based efficacy concerns (Zerbib RCT no difference vs sham).
ACG recommendation: radiofrequency (Stretta) is not recommended as an antireflux alternative.

Step Therapy

Therapy Sequencing and Step Therapy Considerations

Therapy sequencing and step therapy context: many studies and society guidelines require optimization of medical therapy (PPI optimization or demonstrated PPI-dependence/refractoriness) prior to endoscopic or device-based interventions. For TIF specifically, PPI optimization or PPI-dependence is commonly required prior to offering the procedure.

Studies enrolled PPI-dependent or PPI-refractory patients; document prior PPI duration and response (eg, ≥6 months).
No universal step-therapy mandate is specified in this section; check the main policy and member plan for plan-specific step therapy requirements.

Documentation Required

Patient Selection and Exclusion Criteria

Patient selection and exclusion criteria commonly applied include: BMI > 35 kg/m2, large hiatal hernia (eg, >2–3 cm per device/study), advanced esophagitis (LA grade C or D), Barrett's esophagus > specified lengths, esophageal dysmotility, prior foregut surgery, and other comorbidities. Document absence of these exclusions when applicable.

Common exclusions: BMI > 35, hiatal hernia >2–3 cm, esophagitis LA grade C/D, Barrett's esophagus >2 cm, prior esophageal/gastric surgery, esophageal motility disorders.

Billing Rule

Billing, Coding, and Denial Risk

Billing and coding guidance: use the most appropriate CPT/HCPCS code(s) for the service. Claims submitted with services not accompanied by covered codes under the applicable coverage policy will be denied as not covered. When reporting unlisted procedures (eg, G-POEM), include detailed operative report and supporting documentation to substantiate medical necessity and coding.

Claims lacking covered codes will be denied as not covered.
Unlisted CPTs (43999, 43499) require complete operative and clinical documentation to support reimbursement.

Note

Prior Authorization — Where Not Specified / Operational Note

Prior authorization not specified in some referenced lists: absence of an explicit prior authorization requirement in a code list does not imply coverage; review the main policy and the member's benefit plan. No specific authorization or denial instructions are provided in this section — follow the main policy and payer processes.

If prior authorization is not specified in a reference list for a given code, consult the main policy and plan documents.
No authorization/denial instructions are explicitly provided here — use standard payer UR processes.

Note

Revision and Coverage Change Implications

Coverage changes and revision note: recent revisions removed the non-coverage statement for Zenker POEM and changed coverage for G-POEM from not covered to covered for a small subset of patients. These changes may affect prior denials or authorizations — cases previously denied may warrant re-review under the updated policy.

Revision history documents coverage changes (G-POEM added as a covered subset; Z-POEM non-coverage removed).
Prior denials may be affected; consider re-evaluation where appropriate.

Initial managementDietary modification, glycemic control, hydration, prokinetic and antiemetic medications before procedural options

Eckardt symptom score definition

Eckardt score definitionSymptom score 0–12 counting weight loss, dysphagia, chest pain, regurgitation (0–3 points each)

Scoring details0 = none; 1 = occasional/minor; 2 = daily; 3 = each meal (for symptom items); weight loss scored by kg ranges

Severity stagingScores map to clinical stages: 0–1 stage 0; 2–3 stage I; 4–6 stage II; >6 stage III

GCSI — Gastroparesis Cardinal Symptom Index

GCSI purposeGastroparesis Cardinal Symptom Index (GCSI) measures gastroparesis symptom burden and response

Symptoms includedNausea, retching, vomiting, stomach fullness, inability to finish a meal, excessive fullness, loss of appetite, bloating

Use in studiesReported as baseline and follow-up outcome measure in G-POEM literature

D-POEM definition

D-POEM definitionDiverticular POEM: submucosal tunneling and septotomy of esophageal diverticulum septum or cricopharyngeus muscle

Evidence stanceTechnique reported primarily in small case series (n=11–25) with limited follow-up

Coverage implicationInsufficient evidence to support routine coverage for esophageal diverticula or other indications

G-POEM definition

G-POEM definitionGastric POEM (G-POEM): endoscopic pyloromyotomy via prepyloric submucosal tunnel to cut circular/oblique pyloric muscle for refractory gastroparesis

IndicationProposed for selected patients with severe, refractory gastroparesis after conservative therapy fails

Coding noteReported with unlisted CPT codes (e.g., 43999 or 43499) per policy

Stretta definition

Stretta definitionEndoscopic delivery of radiofrequency energy to the gastroesophageal junction (Stretta System) intended to reduce GEJ compliance and reflux symptoms

FDA statusStretta System FDA-cleared for electrosurgical coagulation of tissue for treatment of GERD (FDA 2000; catheter 510(k) 2015)

Evidence summaryStudies report symptomatic and QoL improvements but randomized trials and meta-analyses show conflicting results and heterogeneity

Transoral Incisionless Fundoplication (TIF) definition

TIF definitionTransoral Incisionless Fundoplication (TIF): endoscopic creation of a fundoplication using devices (EsophyX, MUSE) deploying full-thickness fasteners or staples to recreate the gastroesophageal valve

VariantsTIF 2.0 (EsophyX) uses esophagogastric plications above the Z-line with >20 fasteners; MUSE creates a 180° fundoplication with stapling

IndicationPerformed for chronic GERD in selected patients often after PPI failure or to avoid lifelong medication/surgery

Endoluminal gastroplasty/gastroplication definition

Endoluminal gastroplasty/gastroplication definitionEndoscopic techniques placing sutures, plications, or staples at/near the gastroesophageal junction (eg, EndoCinch, Plicator, GERDx, MUSE) to reduce reflux

Device examplesEndoCinch, Bard Endoscopic Suturing System, Plicator, GERDx, EsophyX, MUSE

Regulatory noteDevices varied in FDA status; MUSE and EsophyX have FDA indications while some devices (GERDx, Plicator) lack approval or were withdrawn

Stretta (radiofrequency energy) definition

Stretta (radiofrequency energy) descriptionEndoscopic RF energy delivery to LES intended to reduce transient LES relaxations, decrease GEJ compliance and improve symptoms

Adverse eventsReported events include chest pain, dysphagia, pneumonia; studies limited by small samples and variable follow-up

Evidence qualityRandomized sham-controlled trials and meta-analyses show heterogeneity and inconsistent physiologic benefits

TIF 2.0 (EsophyX) definition

TIF 2.0 (EsophyX) definitionTIF 2.0: transoral fundoplication using EsophyX with esophagogastric plications above the Z-line, typically >20 fasteners, forming a 240° wrap

Device modelsEsophyX2 HD and EsophyX Z (multiple 510(k) clearances) with indications for symptomatic chronic GERD and small hiatal hernia repair adjuncts

Clinical trial contextRCTs comparing TIF2 to PPI or sham reported symptom improvement and variable pH normalization rates

Troublesome regurgitation (trial outcome definition)

Troublesome regurgitation (trial outcome)Defined per Montreal criteria as mild symptoms ≥2 days/week or moderate–severe symptoms >1 day/week; used as primary outcome in TIF trials

Use in trialsMeasured by patient-reported instruments (RDQ, GERD-HRQL) and used to determine elimination of daily troublesome regurgitation

Follow-up reportingElimination rates reported at 6 months to 5 years in TIF TEMPO and related studies

Troublesome regurgitation (Montreal) duplicated definition

Montreal troublesome regurgitationPer Montreal consensus: mild symptoms ≥2 days/week OR moderate–severe symptoms >1 day/week (used in clinical trials)

ApplicationDefines primary symptomatic endpoints in TIF and other GERD device trials

MeasurementAssessed via validated questionnaires (GERD-HRQL, RDQ, RSI)

Abnormal esophageal acid exposure (EAE) — trial definitions

Abnormal esophageal acid exposure (EAE) — trial definitionsExample thresholds used: percent time pH <4 >5.3% on 48-h Bravo or percent time pH<4 ≥4.0% or elevated DeMeester score; definitions varied by trial

Measurement methodsAmbulatory 24–48 hour pH or pH-impedance testing off PPI therapy commonly used to document EAE

Role in eligibilityObjective EAE often required for enrollment in TIF and other anti-reflux device trials

Resection and Plication (RAP) definition

RAP definitionResection and Plication (RAP): limited mucosal resection plus full-thickness plication using OverStitch to recreate a functional gastroesophageal valve

DevicePerformed with Apollo OverStitch endoscopic suturing system (OverStitch FDA-cleared for endoscopic suturing)

EvidencePaucity of peer-reviewed evidence; small series (eg, n=10) and limited follow-up reported

Magnetic Sphincter Augmentation (MSA/LINX) definition

MSA/LINX definitionMagnetic Sphincter Augmentation (LINX): implantable ring of magnetic beads placed at the gastroesophageal junction to augment LES function

Indication and selectionStudied in patients 18–75 with pathologic esophageal acid exposure and PPI-refractory symptoms; exclusion examples include hiatal hernia >3 cm, BMI >35, advanced esophagitis

OutcomesReported reductions in GERD-HRQL and PPI use; device removals and explants reported in follow-up series

POEM definition and CPT mapping

POEM definitionPeroral Endoscopic Myotomy (POEM): endoscopic submucosal tunneling and myotomy to cut esophageal circular muscle for achalasia

CPT mappingReported CPT: 43497 — Lower esophageal myotomy, transoral (POEM)

Clinical contextConsidered endoscopic equivalent to Heller myotomy; lacks an antireflux procedure and may increase GERD risk

G-POEM definition and coding notes (unlisted CPTs)

G-POEM definitionG-POEM: gastric peroral endoscopic pyloromyotomy creating a prepyloric submucosal tunnel and cutting pyloric muscle to treat refractory gastroparesis

Coding noteReported with unlisted CPT codes (43999 or 43499) per policy guidance

Evidence noteConsidered medically necessary for selected refractory gastroparesis patients when criteria met; evidence includes observational studies and meta-analyses

Stretta / ET definition and evidence summary

Stretta / ET evidence summaryEndoscopic RF (Stretta) shows symptom and QoL improvements in some cohorts but RCTs and meta-analyses show heterogeneity and inconsistent physiologic benefit

MechanismProposed to reduce transient LES relaxations and decrease GEJ compliance; exact mechanisms uncertain

SafetyAdverse events reported (chest pain, dysphagia, pneumonia); larger randomized long-term studies needed

Acronyms (POEM, G-POEM, TIF, LINX, Stretta)

AcronymsPOEM = per-oral endoscopic myotomy; G-POEM = gastric per-oral endoscopic pyloromyotomy; TIF = transoral incisionless fundoplication; LINX = magnetic sphincter augmentation; Stretta = endoscopic radiofrequency therapy

UsageAcronyms commonly used across clinical trials, guidelines, and registry reports in GERD/achalasia/gastroparesis literature

Cross-referenceSee policy sections for full procedure names, CPT mappings, and coding guidance

Peroral Endoscopic Myotomy (POEM) — notation of comparative/long-term references

POEM — comparative/long-term notationPOEM has multiple comparative trials and long-term outcome references (eg, Werner et al. RCTs) supporting non-inferiority to Heller myotomy

Clinical considerationsPOEM is complex and should be performed in high-volume centers by experienced operators; competence estimated at 20–40 procedures

Post-procedure issuePOEM lacks an antireflux component and patients are at higher risk for reflux requiring surveillance and possible indefinite PPI therapy

Transoral Incisionless Fundoplication (TIF) — citations and trial mentions

TIF — citations and trial mentionsTIF (EsophyX, MUSE) supported by multiple randomized trials and long-term outcome studies (TEMPO, Trad, Hunter et al.) showing symptom improvement and variable pH normalization

Device variantsEsophyX (510[k] predicates) and MUSE have published multi-year outcomes up to 5–10 years in selected cohorts

Clinical selectionTrials often enrolled patients with small hiatal hernia (<2–3 cm), abnormal pH testing, and persistent PPI-dependent symptoms

Procedure name variants and abbreviations (POEM, G-POEM, TIF, Z-POEM)

Name variants and abbreviationsPOEM, G-POEM, TIF, Z-POEM and similar terms denote peroral endoscopic myotomy variants and transoral fundoplication approaches used interchangeably in literature

Z-POEM noteZ-POEM (Zenker POEM) referenced in revision notes with prior non-coverage removal; considered a POEM variant for Zenker diverticulum

Clinical implicationProcedure naming may affect coding (use appropriate CPT or unlisted code per policy) and coverage determination